期刊文献+

氨甲环酸两种不同用药方式对全髋关节置换围手术期失血量的影响:前瞻性、开放性、随机对照临床试验 被引量:16

Effects of two different tranexamic acid administration methods on perioperative blood loss in total hip arthroplasty: study protocol for a prospective, open-label, randomized, controlled clinical trial
在线阅读 下载PDF
导出
摘要 背景:全髋关节置换中静脉应用和关节腔内注射氨甲环酸能够明显减少患者围手术期失血量、输血量以及输血率,但两种方法的差异尚不明确。目的:试验观察了氨甲环酸两种不同用药方式对全髋关节置换围手术期失血量的影响。方法:研究为前瞻性、单中心、开放性、随机对照临床试验,在中国山东省滕州市中心人民医院完成。纳入单侧全髋关节置换的患者90例,随机分为3组,氨甲环酸静脉应用组30例,于置换开始时将15 mg/kg氨甲环酸稀释于100 m L生理盐水中静滴,缝合深筋膜后关节腔内注射生理盐水20 mL;氨甲环酸关节腔内注射组30例,置换开始时予100 mL生理盐水静滴,缝合深筋膜后关节腔内注射氨甲环酸1.5 g与20 mL生理盐水混合液;对照组:置换开始时予100 m L生理盐水静滴,缝合深筋膜后关节腔内注射生理盐水20 mL。试验的主要观察指标为置换后1,3 d隐性失血量;试验的次要观察指标为术中、置换后1,3 d显性失血量、输血率和平均输血量;其他观察指标为以置换后3个月不良反应发生率变化评价及并发症发生情况。试验经中国山东省滕州市中心人民医院伦理委员会批准(2015-026)。研究符合世界医学会制定的《赫尔辛基宣言》的要求。参与者本人对治疗方案和过程均知情同意,并签署知情同意书。讨论:试验于2015年4月设计,2015年7月开始收集病例,2017年12月完成全部数据分析。试验旨在探讨氨甲环酸静脉应用和关节腔内注射对全髋关节置换围手术期失血量的影响,以确定何种用药方式更加有效,进而为全髋关节置换提供更有效的氨甲环酸使用方式。 BACKGROUND: Reducing perioperative blood loss in total hip arthroplasty is a hot topic for joint surgeons. Both intravenous infusion and intra-articular injection of tranexamic acid significantly reduce perioperative blood loss, blood transfusion volume, and need for blood transfusion in patients undergoing total hip arthroplasty. However, differences between the intravenous and intra-articular methods are not clear.OBJECTIVE: To evaluate the effects of these two tranexamic acid administration methods on perioperative blood loss in patients undergoing total hip arthroplasty.METHODS: We are conducting a prospective, single-center, open-label, randomized, controlled clinical trial at the Tengzhou Central People's Hospital, China. Ninety patients undergoing unilateral total hip arthroplasty have been randomized into three groups. In the intravenous infusion group (n=30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was infused intravenously at the beginning of surgery and 20 mL of physiological saline was injected intra-articularly after deep fascia suturing. In the intra-articular injection group (n=30), 100 mL of physiological saline was infused intravenously at the beginning of surgery and a mixture of 1.5 g tranexamic acid and 20 mL physiological saline was injected intra-articularly after deep fascia suturing. In the control group (n=30), 100 mL of physiological saline was infused intravenously at the beginning of surgery and 20 mL of physiological saline was injected intra-articularly after deep fascia suturing. The primary outcome is hidden blood loss at 1 and 3 days postoperatively. The secondary outcomes are visible blood loss, need for blood transfusion, and mean blood transfusion volume intraoperatively and on days 1 and 3 postoperatively. Other outcomes are the incidence of adverse reactions and complications within 3 months of surgery. The study protocol has been approved by the Ethics Committee of Tengzhou Central People's Hospital of China, approval number 2015-026. All protocols will be performed in accordance with the Ethical Principles for Medical Research Involving Human Subjects in the Declaration of Helsinki. Written informed consent was provided by each patient and their family members after they indicated that they fully understood the treatment plan.DISCUSSION: This trial was designed in April 2015. Cases were collected in July 2015. Data analysis will be finished in December 2017. This study is designed to investigate the effects of intravenous infusion versus intra-articular injection of tranexamic acid on perioperative blood loss in patients undergoing total hip arthroplasty to determine the more effective mode of administration.
出处 《中国组织工程研究》 CAS 北大核心 2017年第15期2314-2319,共6页 Chinese Journal of Tissue Engineering Research
基金 济宁医学院2015年度校级科研计划项目(JY2015KJ042)~~
  • 相关文献

参考文献3

二级参考文献50

  • 1Bierbaum BE,Callaghan JJ,Galante JO,et al.An analysis of blood management in patients having a total hip or knee arthroplasty.J Bone Joint Surg Am,1999,81(1):2-10.
  • 2Lemaire R.Strategies for blood management in orthopaedic and trauma surgery.J Bone Joint Surg Br,2008,90(9):1128-1136.
  • 3Nilsson IM.Clinical pharmacology of aminocaproic and tranexamic acids.J Clin Pathol Suppl(R Coll Pathol),1980,14:41-47.
  • 4Hoylaerts M,Lijnen HR,Collen D.Studies on the mechanism of the antifibri-nolytic action of tranexamic acid.Biochim Biophys Acta,1981,673(1):75-85.
  • 5Benoni G,Fredin H,Knebel R,et al.Blood conservation with tranexamic acid in total hip arthroplasty:a randomized,double-blind study in 40 primary operations.Acta Orthop Scand,2001,72(5):442-448.
  • 6Johansson T,Pettersson LG,Lisander B.Tranexamic acid in total hip arthroplasty saves blood and money:a randomized,double-blind study in 100 patients.Acta Orthop,2005,76(3):314-319.
  • 7Ralley FE,Berta D,Binns V,et al.One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty.Clin Orthop Relat Res,2010,468(7):1905-1911.
  • 8Yamasaki S,Masuhara K,Fuji T.Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases.Int Orthop,2004,28(2):69-73.
  • 9Gillette BP,De Simone LJ,Trousdale RT,et al.Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.Clin Orthop Relat Res,2013,471(1):150-154.
  • 10Mc Cormack PL.Tranexamic acid:a review of its use in the treatment of hyperfibrinolysis.Drugs,2012,72(5):585-617.

共引文献107

同被引文献135

引证文献16

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部